Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276639 · ClinicalTrials.gov registry record · Phase 3
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 901
- Enrollment target
- 20
- Study locations
NCT01276639 is a Phase 3 study of Psoriasis that has completed, run by Pfizer. The registered enrollment target is 901 participants, above the 482-participant average among 125 other Psoriasis trials with a reported enrollment target (87% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT01276639, a Phase 3 study of Psoriasis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 901 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
Conditions Studied
Interventions
- DRUG CP-690,550
- DRUG Placebo/CP-690,550
Study Locations (20)
California
- University of California, Irvine - Dermatology Research - Irvine
- Skin Surgery Medical Group, Inc. - San Diego
- Clinical Science Institute - Santa Monica
Georgia
- Atlanta Dermatology, Vein & Research Center, P.C. - Alpharetta
- Peachtree Dermatology Associates Research Center - Atlanta
- MedaPhase Inc. - Newnan
Florida
- Renstar Medical Research - Ocala
- Academic Alliance in Dermatology - Tampa
Massachusetts
- Tufts Medical Center - Boston
- Massachusetts General Hospital - Clinical Unit for Research Trials and Outcomes in Skin - Boston
New York
- New York University School of Medicine - New York
- Skin Search of Rochester, Inc. - Rochester
North Carolina
- Raleigh Radiology Blue Ridge - Raleigh
- Wake Research Associates - Raleigh
Alabama
- Radiant Research, Inc. - Birmingham
Colorado
- Cherry Creek Research, Inc. - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 901 participants |
| Start Date | 2011-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01276639
The ClinicalTrials.gov registry entry for NCT01276639 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 901 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 482-participant average among 125 other Psoriasis trials with a reported enrollment target (87% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which CP-690,550 is the first listed.
NCT01276639 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Georgia, Florida.
Frequently Asked Questions
What is clinical trial NCT01276639 about?
NCT01276639 is a clinical study titled "A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis". The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
What is the current status of trial NCT01276639?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 901 participants. The study started on 2011-03. Estimated completion is 2013-04.
What conditions does trial NCT01276639 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01276639?
The interventions under investigation include: CP-690,550 (DRUG), Placebo/CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT01276639?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01276639 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.